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Small cell carcinoma of the ovary, hypercalcemic type, is a rare
tumor that typically affects young women. While many women diag-
nosed with this tumor are diagnosed at an early stage, the aggressive
behavior leads to a strikingly poor prognosis. Most women die within
a year of diagnosis.
First described by Dickersin et al. (1982), patients with small cell
carcinoma of the ovary typically present with a unilateral large
tumor. The average age of diagnosis is 24 years old, and the majority
of patients also present with hypercalcemia (62%) (Young et al.,
1994). While Young et al. has presented a large series of cases describ-
ing the histologic features of this tumor type, optimal management
of patients is not well deﬁned. Harrison et al. presented a review of
management of 17 cases in a GCIG study, with poor results noted
(Harrison et al., 2006).
We present here a review of cases previously published and a case
of small cell carcinoma of the ovary, hypercalcemic-type (SCCO-HT),
in a 14 year-old patient. We discuss her surgical and chemotherapy
treatment course with the hope that this will augment the collective
knowledge base to understand this aggressive tumor's sensitivity to
chemotherapy.⁎ Corresponding author at: University of Michigan Medical Center, Department of
Obstetrics and Gynecology, Division of Gynecologic Oncology, 1500 East Medical
Center Drive, L4512WH, Ann Arbor, MI 48109, USA. Fax: +1 734 764 7261.
E-mail address: arvindba@med.umich.edu (A. Bakhru).
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The patient is a 14 year-old nulligravid with BMI of 35 who com-
plained of increasing abdominal pain for two weeks. The pain was
episodic in intensity. CT imaging revealed a 16×15×9 cm complex
left pelvic mass. (Fig. 1). Laboratory testing showed a white blood
cell count of 19, although she was afebrile. She denied any fever,
weight loss, hirsutism, acne, or intermenstrual bleeding. Tumormarkers
showed an LDH of 755 units/L, CA125 of 196.1 units/mL, and CA19-9 of
16 units/mL. Inhibins A and B, AFP, CEA, testosterone, and HCG were
normal. Calcium was normal as well.
She underwent a planned exploratory laparotomy, left salpingo-
oophorectomy, pelvic and para-aortic lymphadenectomy, omentectomy,
and peritoneal biopsies from the bladder peritoneum, posterior cul-
de-sac, right round ligament and fallopian tube, right pericolic gutter,
anterior abdominal wall, and bowel mesentery. The left ovary appeared
irregular, old clots were noted throughout the pelvis. The uterus and
right ovary appeared normal. Shewas optimally debulked to no evidence
of residual disease.
Final pathology revealed poorly differentiated small cell carcinoma
of the ovary, hypercalcemic-type, with microscopic metastases to the
omentum. Lymph nodes and washings were negative for malignancy.
She was diagnosed with Stage 3A high grade small cell carcinoma
of the ovary. Postoperative CA-125 was 65, which declined further to
37.8 prior to the start of chemotherapy. LDH remained elevated at 507.
Adjuvant chemotherapy was planned consisting of vinblastine,
cisplatin, cyclophosphamide, bleomycin, doxorubicin, and etoposide
(VPCBAE) for four cycles followed by planned PBAE for two cycles
(Senekjian et al., 1989; Tewari et al., 1997; Sholler et al., 2005). She
completed the ﬁrst four cycles of VPCBAE only. Autologous stem cell
harvesting was also performed with plans for stem cell transplant.
Her chemotherapy course was complicated by admission with fever
and pancytopenia, hypovolemic shock resulting in acute tubular ne-
crosis, and Grade III oral mucositis. During that hospitalization she
also developed pneumonia. She was treated and discharged without
incident. Supplemental Fig. 2 shows tumor marker progression.
Given that the CA-125 had decreased to 8.4 after completion of
four cycles of VPCBAE, interim PET and CT scans were performed.
Possible metastatic peritoneal implants were noted on PET, with no
notable residual disease on CT scan. CT noted resolution of enlarged
mesenteric lymph nodes and non-enlarged iliac lymph nodes. Given
the discrepancy, another CT scan was performed three weeks later,
which showed a new large pelvicmasswith cystic and solid components
measuring 10.8×12.1×6.7 cm. Peritoneal implants and a new enlarged
Fig. 1. Initial pelvic mass, prior to surgery.
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opsy of abdominal wall lesions was consistent with recurrence. CA-125
rose from 8.4 to 27.5 over the three weeks; LDH rose from 247 to 888.
Supplemental Figs. 3a and b show the PET scan and both CT scans.
She began treatmentwith gemcitabine and taxotere. She completed
two cycles of treatment before increasing pain and work of breathing
required inpatient admission and eventual transfer to the Pediatric
Intensive Care Unit. Ascites continued to accumulate despite multiple
paracentesis; pain and acidosis worsened. Care was eventually with-
drawn once respiratory effort would have required intubation. She
died shortly thereafter, six weeks from deﬁnitive recurrence and six
months from her date of diagnosis.Pathology
On gross examination, a 20×15×8 centimeter left ovarian mass
with tan yellow cut surface was evident. It was predominantly solid
with a few small areas of cystic change and hemorrhage was noted.
The fallopian tube was not involved (Fig. 4).
Histology revealed small cell carcinoma of the ovary, hypercalce-
mic type.
On low power, microscopy reveals sheets of a densely cellular, poor-
ly differentiated malignant neoplasm growing in diffuse sheets withFig. 4. Gross pathology.multifocal necrosis and cystic change. In the areas of necrosis, viable
tumor cells tend to cluster around vessels (so-called peritheliomatous
pattern). Fibroadematous bands separate broad zones of tumor, im-
parting a vaguely lobular appearance. In addition, multiple follicle-like
spaces are noted.
On higher power, medium sized tumor cells are noted with
hyperchromatic, pleomorphic nuclei with coarse chromatin pattern
and prominent nucleoli. The cytoplasm is eccentrically-placed and
eosinophilic. There are numerous mitoses. The tumor cells appear as
moderately large cells with high nucleus to cytoplasm ratio, thus
making this the large-cell variant of small cell carcinoma. The tumor
appears structurally to grow in sheets and occasionally shows follicle-
like spaces. There is abundant necrosis with areas of secondary cystic
change. No areas of classic small with minimal cytoplasm were seen,
hence rendering this the large cell variant, according to Scully. Stroma
is inconspicuous and myxoid (Fig. 5).
Immunohistochemistry is notable for pan-cytokeratin positivity,
focal CD 56, and nuclear WT-1 staining. Pan-cytokeratin stain was
positive (AE1/AE3/CAM5.2). Not unexpected in such a high grade car-
cinoma, cytokeratin staining is positive in a minority cells. Calretinin
staining was focally strongly positive. Melanoma was ruled out with
S-100, Ewings ruled out with CD99, INI-1 ruled out rhabdoid
tumors, and lymphoma ruled out with CD45. Immunohistochemical
results are given in Supplemental Table 1.
Genetic tests performed included karyotyping and EGFR mutation
analysis. Karyotyping of the tumor showed 46, XX. PCR was used to
perform the EGFR mutation analysis (her2); no deletion in exon 19
or L858R substation was found.
Discussion
Small cell carcinoma of the ovary, hypercalcemic type large cell
variant, is a rare tumor that arises in young women with average
age 23–24 (range 10–49) (Young et al., 1994). A review of the litera-
ture notes only a fewwell-documented cases of small cell carcinoma of
the ovary in teenagers. Reports exist by Young et al. (1994), Senekjian
et al. (1989), Dickersin et al. (1982), Di Vagno et al. (2000),
Barondeau et al. (J Pediatr Hematol Oncol. 2010) and Blatt et al. (J
Pediatr Hematol Oncol. 2003).
Young patients with this tumor appear to have a more aggressive
clinical course and grave prognosis than older patients. All recent
cases reported of this tumor in teenagers have demonstrated a similar
clinical course, with each patient dying within two years of diagnosis.
While chemotherapeutic regimen is not speciﬁed in all case reports,
most patients responded to chemotherapy with VPBCAE. Each pa-
tient, however, recurred rapidly with typical clinical course including
pulmonary metastases resulting in anasarca and respiratory distress.
Interestingly, the few teenage survivors of this tumor were described
in the seminal paper describing this disease entity by Young, Oliva,
and Scully Young et al. (1994). In their report, ﬁve cases in teenagers
were described, all with response to treatment. Those that recurred,
tended to do so quickly, but four survived more than two years. The
more typical clinical course, however, is similar to our own patient.
In our case, the tumor grew rapidly from no evidence of disease
after four cycles of VPBCAE to a large pelvic mass with metastases
in three weeks and death within two months.
Vinblastine, cisplatin, bleomycin, cyclophosphamide, doxorubicin,
and etoposide have been used in the treatment of SCO-HT with vary-
ing success (Senekjian et al., 1989; Tewari et al., 1997; Sholler et al.,
2005). Our patient tolerated the regimen well with one admission
for pancytopenia and associated complications. Of the teenagers
presented in the literature, a complete response is typically seen
after four cycles, yet massive recurrence is noted shortly thereafter.
Additional cycles or immediate additional chemotherapy interven-
tionmay be warranted. To treat the recurrence, we chose gemcitabine
and docetaxel, in a similar manner to the treatment of sarcoma. Our
Fig. 5. H&E Histology. Panel A— sheets of tumor cells with ﬁbroepithelial bands and absent stroma; areas of cystic change from necrosis, 4×. Panel B – follicle like spaces are noted,
20×. Panel C — high power view of the tumor cells, 60x. Panel D — microscopic metastasis to the omenum, 10×.
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have examined irinotecan (Isonishi et al., 2008), cisplatin and cyclophos-
phamide and etoposide (Taraszewski et al., 1991), topotecan, and plati-
num and paclitaxel (Harrison et al., 2006); (Di Vagno et al., 2000).
Harrison et al. reported none in their series with survival without cisplat-
in and etoposide and a signiﬁcant beneﬁt to radiotherapy (Harrison et al.,
2006). Whole pelvic radiotherapy was considered in this case given the
rapid regrowth of the tumor, but was not tried in this case.
The histology of SCC-HT is well described by the initial report by
Young et al. (1994). Our report provides updated immunohistochem-
ical staining patterns for this rare tumor type. The staining pattern
typical for tumor cells in SCC-HT is positive for epithelial markers
(cytokeratin positive, EMA), INI-1, WT1, calretinin, CD10, and p53.
Of note, Young et al. reported positive EMA in 8 of 24 cases, but did
not specify whether this was membranous or cytoplasmic staining.
Due to the often non-speciﬁc morphology, other high grade neo-
plasmsmust be excluded, includingmalignantmelanoma, lymphoma,
sex cord-stromal tumors, germ cell tumors, and various sarcomas
(Ewing, rhabdomyosarcoma), and rhabdoid tumors. The misnomers
surrounding the name of this tumor are also of interest. The large
cell variant refers to small cell carcinoma with moderately larger
cells and more abundant cytoplasm with prominent nucleoli. When
no particular area of small cells is seen, this is termed a large cell var-
iant. Secondly, although this case did not have hypercalcemia, absent
hypercalcemia is typical of the large cell variant (Seidman, 1995).
This case is unique in that it documents the aggressive disease
course and poor prognosis of such cases in detail with both imaging
and tumor markers. In three weeks' time, this tumor had a massive
recurrence, progressing from no evidence of disease to a twelve cen-
timeter mass, signiﬁcant ascites, pulmonary metastases, and eventual
death one month later. While the optimal treatment regimen has not
been established, the VPBCAE regimen holds promise, yet results inquick and deadly recurrence in young patients. A case registry
would aid in identiﬁcation of treatment variants to aid future
patients.
Informed consent
Written informed consent was obtained from the patient's family
for publication of this case report and accompanying images. A copy
of the written consent is available for review by the Editor-in-Chief
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